Table I.
Summary of erosive pustular dermatosis-like eruption, other cutaneous adverse effects, and treatments in 3 patients treated with amivantamab
| Variables | Case 1 | Case 2 | Case 3 |
|---|---|---|---|
| Age/sex | 62/F | 73/F | 66/M |
| Type of stage IV lung cancer | Adenocarcinoma | Small cell | Adenocarcinoma |
| Amivantamab course | |||
| Dose | 1050 mg | 1050 mg | 1050 mg |
| Other concurrent anticancer therapy | Osimertinib | ||
| Drug holiday | X | X | X |
| Rechallenge | X | X∗ | |
| Permanent cessation | X | X | |
| Cancer progression on amivantamab | X | X | |
| EPD-like eruption | |||
| Months to onset | 4 | 4 | 13 |
| Staphylococcus aureus–positive culture | X | X | |
| Improvement with drug holiday | X | N/A | X |
| Worsening with amivantamab rechallenge | X | N/A | |
| Resolution with amivantamab cessation | X | X | N/A |
| Control of EPD with amivantamab continuation | N/A | N/A | X† |
| Other cutaneous toxicities | |||
| Acneiform rash | X | X | X |
| Paronychia | X | X | X |
| Pyogenic granuloma | X | ||
| Other skin ulceration/erosion | X‡ | X§ | Xװ |
| Treatment modalities | |||
| Topical antimicrobials | |||
| Mupirocin | X | ||
| Ketoconazole | X | ||
| Systemic antimicrobials | |||
| Doxycycline | X | X | X |
| Trimethoprim-sulfamethoxazole | X | ||
| Dapsone | X | ||
| Steroids | |||
| Fluocinolone | X | X | |
| Triamcinolone | X | ||
| Clobetasol | X | X | |
| Prednisone | X | X | |
| Retinoids | |||
| Isotretinoin | X | X | |
| Acitretin | X | ||
EPD, Erosive pustular dermatosis; N/A, not available.
∗
Restarted on amivantamab with the interval between cycles increased from 2 weeks to 3 weeks.
†
Receiving 50 to 75 mg dapsone.
‡
Scalp nodule.
§
Inframammary lesions.
װ
Scrotal lesions.